أيروجيني — مساعدك الذكي للطيران.
الرائج الآن
Categories
Joint Statement from UK Space Agency, MHRA, Regulatory Innovation Office, and Civil Aviation Authority

Joint Statement from UK Space Agency, MHRA, Regulatory Innovation Office, and Civil Aviation Authority
The UK Space Agency, Medicines and Healthcare products Regulatory Agency (MHRA), Regulatory Innovation Office (RIO) within the Department for Science, Innovation and Technology (DSIT), and Civil Aviation Authority (CAA) have announced a collaborative effort to cultivate a supportive regulatory environment for companies operating in the space, biopharma, and pharmaceutical sectors. This partnership encompasses the development of guidance, regulatory sandboxes, case studies, and engagement with supply chains, underscoring the United Kingdom’s commitment to maintaining a leadership role in space-enabled manufacturing.
Advancing In-Orbit Manufacturing and Regulatory Clarity
A central focus of this collaboration is In-Orbit Manufacturing (IOM), a specialized segment of the broader In-Orbit Servicing, Assembly, and Manufacturing (ISAM) industry. IOM holds significant promise for producing materials and pharmaceuticals in space, potentially achieving superior quality and performance compared to traditional Earth-based manufacturing processes. To explore this potential, the UK Space Agency is funding three feasibility studies, including a £250,000 grant awarded to BioOrbit, a start-up developing a scalable system to crystallize biologic drugs for cancer treatment in orbit. This initiative forms part of the UK Space Agency’s Unlocking Space Portfolio and involves close cooperation between MHRA, the UK Space Agency, and BioOrbit to establish clear regulatory pathways for space-based pharmaceutical production.
Microgravity environments offer unique advantages for drug formulation, particularly for biologics and protein-based medicines such as monoclonal antibodies, vaccines, and insulin. These conditions can improve drug solubility, purity, crystallization, and stability, which may enhance drug delivery while reducing manufacturing risks and costs. The ability to manufacture pharmaceuticals in orbit could revolutionize precision medicine, improve drug stability for populations in remote or crisis-affected areas, and reinforce the UK’s position at the forefront of innovative pharmaceutical manufacturing.
The MHRA’s regulatory framework applies to both conventional and novel medicines, including those developed through advanced manufacturing techniques in unique environments like microgravity. Building on its pioneering regulatory pathways—such as the world-first framework for decentralized and modular manufacturing introduced in 2025—the MHRA collaborates with industry stakeholders to ensure that regulations remain fit for purpose. This approach balances the need to foster innovation with the imperative to uphold rigorous standards of safety, quality, and public health protection.
BioOrbit’s feasibility study, scheduled to run until March 2026, aims to clarify the regulatory requirements specific to in-orbit pharmaceutical manufacturing. This work will assess the applicability of existing terrestrial regulations to space-based production, providing essential clarity for innovators in the space biotechnology sector.
Addressing Broader Regulatory and Market Challenges
Recent incidents have underscored the critical importance of robust regulatory oversight. A fatal infection linked to non-sterile alcohol-free wipes prompted warnings from the UK Health Security Agency and MHRA, highlighting the need for stringent product safety standards. Such events can lead to heightened regulatory scrutiny, shifts in consumer preferences toward sterile products, and competitive responses including enhanced sterilization processes and public safety assurances.
In the space sector, evolving regulatory measures also influence market dynamics. New, stricter reentry regulations for Starlink satellites, designed to mitigate orbital debris risks, may impact UK investors by increasing liability, insurance costs, and operational timelines. In response, the UK government has introduced a cap on launch liability to bolster the domestic rocket industry and address competitive disadvantages, particularly in the wake of the collapse of Orbex.
As the UK continues to advance in space and pharmaceutical innovation, its regulatory agencies remain committed to enabling technological progress while safeguarding public health and supporting the resilience of industry.

AJW Group Renews Partnership with ASL Aviation to Support A330ceo Fleet

Could AI Cause a Jet Engine Shortage Similar to the Chip Crisis?

Finnair's Commitment to Sustainable Aviation and Value Chains

Women Leaders Shaping the Future of Passenger Experience

Marshall Aerospace’s 115-Year Evolution from Cars to C-130s

Advancing Sustainable Aviation Goals for 2050

Sabre Introduces New AI-Driven Platform

Photo of the Day: Special Delivery

GOL CEO Confirms Possible Arrival of A330neo Widebody Aircraft
